SPRY NASDAQ
ARS Pharmaceuticals, Inc.
1W: -7.3%
1M: -3.9%
3M: -30.9%
YTD: -65.9%
1Y: -59.4%
3Y: +16.0%
5Y: -58.2%
$3.73
-0.19 (-4.85%)
After Hours: $3.68 (-0.05, -1.21%)
Weekly Expected Move ±8.9%
$3
$4
$4
$4
$5
Credit Risk of going bust: higher than 81% of companies Debt: 30.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.22 (down 94%), ARS Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $171.6M against a stock market value of $389.8M.
Distance to default 2.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $85.8M (short-term plus half of long-term), stock volatility 75.1%; Altman Z'' -7.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.22 (down 94%), ARS Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $171.6M against a stock market value of $389.8M.
Distance to default 2.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $85.8M (short-term plus half of long-term), stock volatility 75.1%; Altman Z'' -7.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$389.8M
52W Range3.81-13.15
Volume1,433,829
Avg Volume1,890,014
Beta0.88
Dividend—
Analyst Ratings
Company Info
CEODonn Casale
Employees195
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-04
Websitears-pharma.com
11682 El Camino Real
San Diego, CA 92130
US
San Diego, CA 92130
US
858 335 1300
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Latest News
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Small-cap stocks with weak momentum grades and steep YTD losses
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Pentair plc (PNR), Datavault AI Inc. (DVLT), and ARS Pharmaceuticals, Inc. (SPRY) Announced by Holzer & Holzer, LLC
Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $28.20
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Casale Donn | A-Award | 1,036,923 | $4.12 | 2026-10-01 |
| Smith Margaret Ekins | A-Award | 1,001,738 | $5.77 | 2026-09-01 |
| Smith Margaret Ekins | 0 | — | 2026-08-17 | |
| Casale Donn | A-Award | 898,456 | $7.96 | 2026-07-01 |
| Shah Pratik | A-Award | 30,000 | $10.54 | 2026-06-24 |